Research code: 1234
Ethics code: IR.IUMS.FMD.REC.1400.596
Clinical trials code: 12
Iran University of Medical Sciences , drt.pediatrician@gmail.com
Abstract: (170 Views)
Introduction: This study investigates the renal function outcome of patients treated with Remdesivir.
Methods: This cohort and prospective study was conducted in the internal departments of Hazrat Ali Asghar Hospital of Iran University of Medical Science. The entry criteria were: age between 1 to 18 years, no previous history of kidney disease, and diagnosed with severe COVID-19 which were indicated to receive Remdesivir. Remdesivir were administered to the patients at days 2-5 of admission in same protocols. Clinical features, electrolytes, inflammatory, and renal function laboratory test were examined in first day of treatment and after 12 months.
Results: In this study, 114 patients with COVID-19 were examined in two categories of No MISC COVID-19 and MISC COVID-19. Men were dominant in No MISC and MISC group with 25 cases (54.3 percent) and 42 cases (61.8 percent), respectively. Also, in No MISC and MISC group 19 cases (41.3%) and 36 cases (52.9%) were under 5 years old, respectively. The most organs involved in these two groups were Gastrointestinal with 33 cases (71.7%) and 58 cases (85.3%) respectively. There were 6 cases (13.0%) and 38 cases (55.9%) of AKI kidney symptoms in the two groups of No MISC and MISC COVID-19 patients, respectively. After 1 year of follow-up, there was no significant difference in blood test findings between the No MISC and MISC COVID-19 groups (P>0.05). Abnormal ultrasound findings, Venous Blood Gas (VBG) HCO3, Urinalysis (U/A) Hematuria and U/A WBC were significantly changed to normal value after one year compared to before (P<0.05). In the MISC COVID-19 group, all renal function parameters were significantly changed to normal limits (P<0.05). Abnormal ultrasound findings, Creatinine, U/A protein and the presence of U/A micro albumin in MISC COVID-19 group were significantly more than No MISC COVID-19 patients (P<0.05).
Conclusion: MISC COVID-19 patients develop more AKI symptoms while receiving Remdesivir at admission baseline. After 1-year follow up there is no difference in COVID-19 outcome between MISC and No MISC patients.
Key words: Covid-19, MIS-C, Remdesivir, AKI, CKD
Methods: This cohort and prospective study was conducted in the internal departments of Hazrat Ali Asghar Hospital of Iran University of Medical Science. The entry criteria were: age between 1 to 18 years, no previous history of kidney disease, and diagnosed with severe COVID-19 which were indicated to receive Remdesivir. Remdesivir were administered to the patients at days 2-5 of admission in same protocols. Clinical features, electrolytes, inflammatory, and renal function laboratory test were examined in first day of treatment and after 12 months.
Results: In this study, 114 patients with COVID-19 were examined in two categories of No MISC COVID-19 and MISC COVID-19. Men were dominant in No MISC and MISC group with 25 cases (54.3 percent) and 42 cases (61.8 percent), respectively. Also, in No MISC and MISC group 19 cases (41.3%) and 36 cases (52.9%) were under 5 years old, respectively. The most organs involved in these two groups were Gastrointestinal with 33 cases (71.7%) and 58 cases (85.3%) respectively. There were 6 cases (13.0%) and 38 cases (55.9%) of AKI kidney symptoms in the two groups of No MISC and MISC COVID-19 patients, respectively. After 1 year of follow-up, there was no significant difference in blood test findings between the No MISC and MISC COVID-19 groups (P>0.05). Abnormal ultrasound findings, Venous Blood Gas (VBG) HCO3, Urinalysis (U/A) Hematuria and U/A WBC were significantly changed to normal value after one year compared to before (P<0.05). In the MISC COVID-19 group, all renal function parameters were significantly changed to normal limits (P<0.05). Abnormal ultrasound findings, Creatinine, U/A protein and the presence of U/A micro albumin in MISC COVID-19 group were significantly more than No MISC COVID-19 patients (P<0.05).
Conclusion: MISC COVID-19 patients develop more AKI symptoms while receiving Remdesivir at admission baseline. After 1-year follow up there is no difference in COVID-19 outcome between MISC and No MISC patients.
Key words: Covid-19, MIS-C, Remdesivir, AKI, CKD
Type of Study: Research |
Subject:
Pediatric Nephrology
Send email to the article author
